David Nutt: Amanita Muscaria Due For More Research – The Daily Dive
Today on the Daily Dive, our host Cassandra Leah sits down with Dr David Nutt, a highly experienced neuropsychopharmacologist, the
Read moreToday on the Daily Dive, our host Cassandra Leah sits down with Dr David Nutt, a highly experienced neuropsychopharmacologist, the
Read moreYesterday morning, Canaccord Genuity released a primer into five psychedelic companies that they “believe could mature into leaders within their
Read morePsyched Wellness (CSE: PSYC) this morning issued a brief press release related to the ongoing pre-clinical trial of its muscimol
Read morePsyched Wellness (CSE: PSYC) has closed its previously announced private placement. The company managed to raise an impressive $6.6 million
Read morePsyched Wellness (CSE: PSYC) this morning provided an update on its study to determine the therapeutic aspects of muscimol as
Read morePsyched Wellness (CSE: PSYC) has increased the size of its bought deal private placement as a result of strong demand
Read morePsyched Wellness (CSE: PSYC) is the latest psychedelics-focused firm to announce a bought deal financing, with the company this evening
Read morePsyched Wellness (CSE: PSYC) is looking to build up its portfolio of intellectual property. The company this morning announced that
Read morePsyched Wellness (CSE: PSYC) has completed the first step in identifying the medicinal potential of Muscimol for both mental and
Read morePsyched Wellness (CSE: PSYC) has begun yet another study related to that of the Amanita Muscaria mushroom. The latest research
Read more